NCT06520514View on ClinicalTrials.gov

A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

February 4, 2025

Conditions
Healthy
Interventions
DRUG

Spesolimab

Spesolimab

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY